Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma:…
Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of patients in a Phase II study, researchers from The…